Memantine for Agitation in Dementia.

Trial Profile

Memantine for Agitation in Dementia.

Completed
Phase of Trial: Phase IV

Latest Information Update: 27 Feb 2017

At a glance

  • Drugs Memantine (Primary)
  • Indications Agitation; Alzheimer's disease
  • Focus Pharmacogenomic; Therapeutic Use
  • Acronyms MAGD; MAGD-Genes
  • Most Recent Events

    • 30 Jan 2014 Accruel to date is 93% according to United Kingdom Clinical Research Network record (3986).
    • 22 Oct 2012 New source identified and integrated (ISRCTN: Current Controlled Trials: 24953404).
    • 18 Feb 2012 Status changed from recruiting to completed as reported by United Kingdom Clinical Research Network record (9420).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top